The clearance of Alife Health’s Embryo Predict follows a 440-patient randomized trial across seven clinics, marking the first regulatory approvals of AI in IVF embryo selection for Day 5-7 blastocsysts
The Next Generation of IVF Technology Receives FDA Clearance
Artificial intelligence has been explored in IVF laboratories for years, most often as a research tool or retrospective decision-support system. But it has rarely been cleared to directly inform one of the most subjective and consequential decisions in embryology: which embryo to transfer.
That changed with the FDA clearance of Embryo Predict, an AI-powered embryo assessment tool developed by Alife Health. The system is intended to support embryo transfer decisions in U.S. fertility clinics and isthe first commercially available AI embryo assessment platform to receive FDA clearance for Day 5-7 blastocysts.
The clearance places AI directly into a regulated clinical workflow inside IVF labs, where embryologists have traditionally relied on morphological grading and professional judgment to guide embryo selection, cryopreservation, and transfer strategy. Rather than replacing that expertise, Embryo Predict is positioned as a decision-support layer in a process that can carry significant implications patients and patient counseling.
The milestone also signals a shift in how reproductive medicine regulators may evaluate artificial intelligence tools going forward. In addition to FDA review, Embryo Predict was supported by prospective, randomized, multicenter clinical evidence involving 440 patients across seven U.S. fertility clinics—placing it among the more rigorously studied AI systems in reproductive medicine to date.
FDA-Cleared AI Is Now Changing How IVF Labs Select Embryos
Embryo Predict brings randomized clinical evidence into IVF’s most subjective decision—embryo selection inside the lab.
Artificial intelligence has officially entered regulated IVF decision-making. Embryo Predict is:
FDA-cleared for use in U.S. fertility clinics
Validated in a 440-patient, 7-clinic randomized trial
Built for Day 5–7 blastocyst embryo assessment
Designed to support—not replace—embryologist judgment
Associated with 72.9% vs 68.0% clinical pregnancy outcomes in study arms, meeting its non-inferiority endpoint.
Randomized Evidence Supported the Regulatory Review
The FDA clearance was supported by a prospective, randomized, multicenter trial involving 440 patients across seven U.S. fertility clinics. The study compared AI-assisted embryo assessment with conventional embryo evaluation and became one of the largest randomized studies examining AI-assisted embryo selection.
According to results previously reported by Inside Reproductive Health, clinical pregnancy occurred in 72.9% of patients in the AI-supported arm compared with 68.0% in the traditional morphology arm. The trial met its pre-specified non-inferiority endpoint, supporting the use of AI-assisted embryo assessment within clinical practice.
The study stands out because much of the fertility industry's AI activity has been supported by retrospective analyses, validation studies, or workflow metrics. Randomized evidence remains comparatively uncommon despite growing interest in artificial intelligence across reproductive medicine.
For clinic executives, laboratory directors, and physicians evaluating new technologies, the combination of randomized evidence and FDA clearance provides a different level of scrutiny than performance claims alone. The approval may influence how future fertility AI products are assessed by both providers and regulators.
The Approval Reflects a Broader Expansion of AI Across IVF
The clearance arrives as fertility providers continue exploring how artificial intelligence can support clinical and operational decision-making. AI tools are increasingly being used for scheduling, forecasting, patient engagement, workflow management, and laboratory support across fertility organizations.
Embryo Predict represents one part of Alife Health's broader fertility technology portfolio. The company also develops Schedule Predict, a scheduling optimization platform, and Success Predictor, a patient-facing family planning tool. Together, the products reflect an effort to introduce data-driven decision support across multiple stages of the IVF process.
Embryo Predict is indicated for Day 5, Day 6, and Day 7 blastocyst-stage embryos that embryologists have already determined are suitable for transfer. The software provides additional information when multiple embryos qualify for transfer or cryopreservation, while leaving final clinical decisions with the care team. The product also holds CE Mark certification under the European Union Medical Device Regulation.
For the fertility industry, the approval may ultimately be remembered less for a single software product than for what it represents. AI has been discussed as a future component of fertility care for years. FDA clearance supported by randomized clinical evidence moves that discussion closer to routine clinical practice and establishes a regulatory pathway that future fertility AI companies may seek to follow.
FDA-Cleared AI Is Now Changing How IVF Labs Select Embryos
Embryo Predict brings randomized clinical evidence into IVF’s most subjective decision—embryo selection inside the lab.
Artificial intelligence has officially entered regulated IVF decision-making. Embryo Predict is:
FDA-cleared for use in U.S. fertility clinics
Validated in a 440-patient, 7-clinic randomized trial
Built for Day 5–7 blastocyst embryo assessment
Designed to support—not replace—embryologist judgment
Associated with 72.9% vs 68.0% clinical pregnancy outcomes in study arms, meeting its non-inferiority endpoint.